Abstract：OBJECTIVE: To investigate the variance of antibiotic resistance of Acinetobacter Baumanii isolated from children in Wuhan between 2006 and 2008. METHODS: Bacterial susceptibility testing was carried out by the Kirby-Bauer method in 679 strains of Acinetobacter Baumanii isolated in Wuhan Children’s Hospital between 2006 and 2008. The results were assessed according to the guidelines of the Clinical and Laboratory Standards Institute (2008). RESULTS: The nonsusceptible rates of Acinetobacter Baumanii to ceftazidime, cefepime and piperacillin/sulbactam increased significantly in 2007 compared with those in 2006 (P<0.05). By comparing the results of 2007, it was suggested that the nonsusceptible rates of Acinetobacter Baumanii to ceftazidime, cefepime, piperacillin/sulbactam, cefoperazone/sulbactam, imipenem and meropenem increased significantly in 2008 (P<0.05). CONCLUSIONS: The nonsusceptible rates of Acinetobacter Baumanii to β-lactam antibiotics in children from Wuhan increased significantly year by year between 2006 and 2008.［Chin J Contemp Pediatr, 2010, 12 (8):613-615］
YU Tao,BAO Lian-Sheng,YANG Lao-Rong et al. Antibiotic resistance of Acinetobacter Baumanii isolated from children in Wuhan between 2006 and 2008[J]. CJCP, 2010, 12(08): 613-615.
［1］Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen［J］. Clin Microbiol Rev, 2008, 21 (3):538-582.
［2］Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology［J］.Clin Microbiol Infec, 2006, 12(9):826-836.
［3］Pauline DM, Laurent P, Patrice N. Functional analysis of insertion sequence ISAba1, responsible for genomic plasticity of Acinetobacter baumannii［J］. J Bacteriol, 2009,191(7):2414-2418.
［4］Livermore DM, Hill RL, Thomson H, Charlett A, Turton JF, Pike R, et al. Antimicrobial treatment and clinical outcome for infections with carbapenem-and multiply-resistant Acinetobacter baumannii around London［J］. Int J Antimicrob Agents, 2010, 35 (1):19-24.
